Prospective study of fatty acid synthetase (FAS) expression in breast cancer and progression of disease

  • Authors:
    • R Hahnel
  • View Affiliations

  • Published online on: August 1, 1996     https://doi.org/10.3892/ijo.9.2.253
  • Pages: 253-255
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fatty acid synthetase (FAS) mRNA was determined in breast carcinomas of 91 patients. The patients were followed for an average of 47 months. Disease-free survival and overall survival were compared with the expression of FAS-mRNA in the tumour. Sixty-five patients remained disease-free during the follow-up period; twenty-six had recurrent disease, and of those 18 died of the disease. Seventy-five percent of the tumours had low FAS-mRNA levels and there were fewer deaths in this group of patients (15%) than in that with high FAS-mRNA levels (35%). The proportion of recurrences was also smaller in the group with low FAS-mRNA. The probability of survival for five years was over 80% for the low FAS-mRNA group, and about 50% for the high FAS-mRNA group.

Related Articles

Journal Cover

August 1996
Volume 9 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hahnel R: Prospective study of fatty acid synthetase (FAS) expression in breast cancer and progression of disease. Int J Oncol 9: 253-255, 1996
APA
Hahnel, R. (1996). Prospective study of fatty acid synthetase (FAS) expression in breast cancer and progression of disease. International Journal of Oncology, 9, 253-255. https://doi.org/10.3892/ijo.9.2.253
MLA
Hahnel, R."Prospective study of fatty acid synthetase (FAS) expression in breast cancer and progression of disease". International Journal of Oncology 9.2 (1996): 253-255.
Chicago
Hahnel, R."Prospective study of fatty acid synthetase (FAS) expression in breast cancer and progression of disease". International Journal of Oncology 9, no. 2 (1996): 253-255. https://doi.org/10.3892/ijo.9.2.253